Compare Quest Diagnostics Inc (DGX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Verizon Communications Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Verizon Communications Inc trades at $41.84 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 7.6× Quest Diagnostics Inc's market cap, and Verizon Communications Inc pays the higher dividend (6.11%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Verizon Communications Inc for 109 Days on average.
| DGX | VZ | |
|---|---|---|
Market Cap | $25.48B | $192.57B |
Volume | 941,866 | 20,940,094 |
Sector | Health | Media |
52-Week High | $247.45 | $51.45 |
52-Week Low | $173.49 | $38.40 |
Typical Hold Time | 56 Days | 109 Days |
Enterprise Value | $31.23B | $379.28B |
Dividend Yield | 1.49% | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Verizon (VZ) trades at $41.65, down 9% today, with bearish technical signals but solid fundamentals. The stock shows consistent earnings beats (Q4 2025-Q2 2026) and maintains strong cash flow ($37.1B operating cash flow in 2025). Recent news highlights Verizon's joint venture with AT&T and T-Mobile to expand coverage and the election of Charles Phillips to the board (GlobeNewsWire, September 29, 2026).
Outlook: Attractive for income investors with a 6.8% dividend yield and stable cash flow, but high debt ($144B total debt) and competitive pressures pose risks. Analyst consensus price target of $48.17 suggests 16% upside, though technical indicators remain bearish near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
